Cargando…

Characterisation of endogenous A(2A) and A(2B) receptor-mediated cyclic AMP responses in HEK 293 cells using the GloSensor™ biosensor: Evidence for an allosteric mechanism of action for the A(2B)-selective antagonist PSB 603

Endogenous adenosine A(2B) receptors (A(2B)AR) mediate cAMP accumulation in HEK 293 cells. Here we have used a biosensor to investigate the mechanism of action of the A(2B)AR antagonist PSB 603 in HEK 293 cells. The A(2A) agonist CGS 21680 elicited a small response in these cells (circa 20% of that...

Descripción completa

Detalles Bibliográficos
Autores principales: Goulding, Joelle, May, Lauren T., Hill, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770336/
https://www.ncbi.nlm.nih.gov/pubmed/29106905
http://dx.doi.org/10.1016/j.bcp.2017.10.013
Descripción
Sumario:Endogenous adenosine A(2B) receptors (A(2B)AR) mediate cAMP accumulation in HEK 293 cells. Here we have used a biosensor to investigate the mechanism of action of the A(2B)AR antagonist PSB 603 in HEK 293 cells. The A(2A) agonist CGS 21680 elicited a small response in these cells (circa 20% of that obtained with NECA), suggesting that they also contain a small population of A(2A) receptors. The responses to NECA and adenosine were antagonised by PSB 603, but not by the selective A(2A)AR antagonist SCH 58261. In contrast, CGS 21680 responses were not antagonised by high concentrations of PSB 603, but were sensitive to inhibition by SCH 58261. Analysis of the effect of increasing concentrations of PSB 603 on the response to NECA indicated a non-competitive mode of action yielding a marked reduction in the NECA E(MAX) with no significant effect on EC(50) values. Kinetics analysis of the effect of PSB 603 on the A(2B)AR-mediated NECA responses confirmed a saturable effect that was consistent with an allosteric mode of antagonism. The possibility that PSB 603 acts as a negative allosteric modulator of A(2B)AR suggests new approaches to the development of therapeutic agents to treat conditions where adenosine levels are high.